LONDON, UK – June 1, 2022 – ºÚÁϲ»´òìÈ (ºÚÁϲ»´òìÈ) has appointed Dr Michael Kipping as Director of Medical Technologies for Europe, and Nicole Small as Senior Manager of the Medical Technology team.
Prior to joining ºÚÁϲ»´òìÈ, Michael was Health Innovation Lead at Innovate UK (UKRI) responsible for running the primary grant funding program that supports innovative UK health and life science businesses. He also worked closely with stakeholders in government, industry and academia to explore and develop a proposal for a UK Centre of Excellence for Regulatory Science & Innovation (UK CERSI).
Nicole was previously a senior manager at the Medicines and Healthcare Products Regulatory Agency (MHRA) Devices Safety and Surveillance division. She has led major change, educational and operational programs to ensure the safety of devices driven by benefit-risk assessments, and she led the agency’s COVID-19 response to secure the UK supply chain’s protective medical devices and PPE.
In his position at ºÚÁϲ»´òìÈ, Michael will drive the growth of the medical business across Europe.
Nicole will be forming a new team focused on enabling medical technology manufacturers to navigate the complex field of market access and the testing requirements necessary for safety and performance. She will also work with UK and European regulatory agencies and health institutions to expand ºÚÁϲ»´òìÈ’s service offering in that field.
Matt Hopkinson, EVP of EMEAA at ºÚÁϲ»´òìÈ, said: “We’re pleased to have Michael and Nicole join our team at ºÚÁϲ»´òìÈ. As we build a highly experienced and credible team supporting the medical industry, their medical device expertise across clinical, technical, regulatory and business applications will be an incredible asset. They will act as an essential bridge between ºÚÁϲ»´òìÈ’s world-class testing and assurance capabilities and the manufacturers, navigating highly complex and evolving requirements.
“A core part of our strategy includes the development of our medical end-market, and building our team of people with specific experience in the safety and performance of medical technologies will support that growth.”
ºÚÁϲ»´òìÈ provides comprehensive medical device services from feasibility and R&D, to product development and production quality control. It offers a full suite of medical device testing, including mechanical testing, product testing, material characterization and microbiological evaluation.
About ºÚÁϲ»´òìÈ
The ºÚÁϲ»´òìÈ Group is one of the world’s leading global providers of testing, inspection and certification services for a diverse range of products, materials and technologies in advanced industrial supply chains where failure in use is not an option. Headquartered in London, UK, ºÚÁϲ»´òìÈ’s c 7,000 scientists, engineers and technologists, working in our global network of over 200 laboratories, support customers from early R&D, through complex regulatory approvals and into production ensuring their products are safe, sustainable and achieve market access.
In 2021, ºÚÁϲ»´òìÈ set out its new, industry leading environmental commitments, adopting science-based targets and committing to net zero emissions across its entire global business by 2035. These environmental commitments follow ºÚÁϲ»´òìÈ’s achievement of the highest ESG ranking in the testing, inspection and certification industry from Sustainalytics, a global leader in ESG research and data.
For more information about ºÚÁϲ»´òìÈ, please visit our website, connect with us on and and subscribe to our channel.
Media contacts:
Devan LaBrash, Pagoda Public Relations
T: +44 (0) 131 556 0770
E: devan.labrash@pagodapr.com